FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088580940> ?p ?o ?g. }

• W3088580940 endingPage "201" @default.
• W3088580940 startingPage "201" @default.
• W3088580940 abstract "In secondary prevention, the 2019 ESC guidelines recommend achieving LDL cholesterol below 1.4 mmol/l and decreasing over 50% of its baseline value. After myocardial infarction (MI), it has been debated whether MI inflammation could influence lipid profile and thus response to lipid lowering therapy. We investigated whether inflammation in the acute phase MI could influence LLT effect on LDL-c reduction at 1-month follow-up. We retrospectively included consecutive patients admitted for an acute ST-elevation MI (STEMI) between October 2014 and December 2017. Clinical characteristics, lipid profile and CRP were collected at baseline within the first 24 h and lipid profile at 1-month follow-up. We compared in LLT naïve patients the LLT response variability according to baseline median CRP (low-CRP vs. high-CRP group) and the percentages of patients achieving goals and targets according to 2019 guidelines (% achieving an LDL-c < 1.4 mmol/l and % decreasing over 50%). We included 209 STEMI patients. Baseline and 1-month LDL-c was 3.3 ± 0.9 and 1.8 ± 0.6 mmol/L respectively. Baseline median CRP was 4.0 [1.9–9.4] mg/L, and baseline LDL-c was not different according to CRP group. More than 95% of patients were discharged with atorvastatin 80 mg or rosuvastatin 20 mg, but ezetimibe in only 8 patients. In 187 LLT naïve patients, LLT response profile was not different according to baseline median CRP (figure) with a mean LDL-c decrease of 42 ± 20% in low-CRP and 37 ± 25% in high-CRP patients ( P = 0.1). The number of patients achieving a LDL-c reduction over 50% was 35 (38%) and 34 (37%) ( P = 0.1). Only 41(20%) patients achieved a LDL-c < 1.4 mmol/L at 1-month ( Fig. 1 ). After STEMI, 1-month LDL-c reduction by mainly high-dose statin was not significantly modified by early inflammation when baseline LDL measured at admission. LDL-c control at 1-month remains scarce according to the 2019 ESC guidelines." @default.
• W3088580940 created "2020-10-01" @default.
• W3088580940 creator A5016269741 @default.
• W3088580940 creator A5022012473 @default.
• W3088580940 creator A5022272687 @default.
• W3088580940 creator A5026854649 @default.
• W3088580940 creator A5039936186 @default.
• W3088580940 creator A5042601884 @default.
• W3088580940 creator A5048233618 @default.
• W3088580940 creator A5074291231 @default.
• W3088580940 date "2020-10-01" @default.
• W3088580940 modified "2023-09-26" @default.
• W3088580940 title "LDL cholesterol reduction by lipid lowering therapy after acute myocardial infarction is not significantly influenced by baseline systemic inflammation" @default.
• W3088580940 doi "https://doi.org/10.1016/j.acvdsp.2020.03.006" @default.
• W3088580940 hasPublicationYear "2020" @default.
• W3088580940 type Work @default.
• W3088580940 sameAs 3088580940 @default.
• W3088580940 citedByCount "0" @default.
• W3088580940 crossrefType "journal-article" @default.
• W3088580940 hasAuthorship W3088580940A5016269741 @default.
• W3088580940 hasAuthorship W3088580940A5022012473 @default.
• W3088580940 hasAuthorship W3088580940A5022272687 @default.
• W3088580940 hasAuthorship W3088580940A5026854649 @default.
• W3088580940 hasAuthorship W3088580940A5039936186 @default.
• W3088580940 hasAuthorship W3088580940A5042601884 @default.
• W3088580940 hasAuthorship W3088580940A5048233618 @default.
• W3088580940 hasAuthorship W3088580940A5074291231 @default.
• W3088580940 hasConcept C126322002 @default.
• W3088580940 hasConcept C164705383 @default.
• W3088580940 hasConcept C2776839432 @default.
• W3088580940 hasConcept C2776914184 @default.
• W3088580940 hasConcept C2777482532 @default.
• W3088580940 hasConcept C2778163477 @default.
• W3088580940 hasConcept C2778270857 @default.
• W3088580940 hasConcept C2778657065 @default.
• W3088580940 hasConcept C2780499067 @default.
• W3088580940 hasConcept C2781195455 @default.
• W3088580940 hasConcept C500558357 @default.
• W3088580940 hasConcept C71924100 @default.
• W3088580940 hasConcept C90924648 @default.
• W3088580940 hasConceptScore W3088580940C126322002 @default.
• W3088580940 hasConceptScore W3088580940C164705383 @default.
• W3088580940 hasConceptScore W3088580940C2776839432 @default.
• W3088580940 hasConceptScore W3088580940C2776914184 @default.
• W3088580940 hasConceptScore W3088580940C2777482532 @default.
• W3088580940 hasConceptScore W3088580940C2778163477 @default.
• W3088580940 hasConceptScore W3088580940C2778270857 @default.
• W3088580940 hasConceptScore W3088580940C2778657065 @default.
• W3088580940 hasConceptScore W3088580940C2780499067 @default.
• W3088580940 hasConceptScore W3088580940C2781195455 @default.
• W3088580940 hasConceptScore W3088580940C500558357 @default.
• W3088580940 hasConceptScore W3088580940C71924100 @default.
• W3088580940 hasConceptScore W3088580940C90924648 @default.
• W3088580940 hasIssue "2-4" @default.
• W3088580940 hasLocation W30885809401 @default.
• W3088580940 hasOpenAccess W3088580940 @default.
• W3088580940 hasPrimaryLocation W30885809401 @default.
• W3088580940 hasRelatedWork W1987424073 @default.
• W3088580940 hasRelatedWork W2032483368 @default.
• W3088580940 hasRelatedWork W2064937691 @default.
• W3088580940 hasRelatedWork W2070903383 @default.
• W3088580940 hasRelatedWork W2904558057 @default.
• W3088580940 hasRelatedWork W2950712637 @default.
• W3088580940 hasRelatedWork W3121632135 @default.
• W3088580940 hasRelatedWork W3127102875 @default.
• W3088580940 hasRelatedWork W4284989037 @default.
• W3088580940 hasRelatedWork W2522703717 @default.
• W3088580940 hasVolume "12" @default.
• W3088580940 isParatext "false" @default.
• W3088580940 isRetracted "false" @default.
• W3088580940 magId "3088580940" @default.
• W3088580940 workType "article" @default.